September 2026
- Oveporexton for Narcolepsy Type 1 — Results from Two Phase 3 Trials
- The Legacy of Orexin (Hypocretin) Research in Narcolepsy and Beyond
- Targeted Treatment for Narcolepsy Type 1
- Reengineering Coagulation with a Bispecific Antibody
- A Step Forward — Obinutuzumab for Membranous Nephropathy
- FDA’s New Framework for Psychedelic Drugs
- Complete Regression of Hepatoblastoma after Interleukin-15– and Interleukin-21–Coexpressing CAR T-Cell Therapy
- Neuroinvasive Trichodysplasia Spinulosa–Associated Polyomavirus Infection
- Ultrasound-Facilitated, Catheter-Directed Fibrinolysis for Acute Pulmonary Embolism
- Ensitrelvir for Covid-19 Postexposure Prophylaxis
- Zongertinib in HER2-Mutant Non–Small-Cell Lung Cancer
- Treatment Decisions in Multiple Myeloma
- Grey Turner’s Sign
- Advancing Gene Editing for Children with Hemoglobinopathies
- Outbreak of Severe Methemoglobinemia during Maritime Migration
- Case 25-2026: A 65-Year-Old Man with Fever and Rash
- Tozorakimab to Prevent COPD Exacerbations
- AI-Based Translation of Discharge Instructions — Aligning Policy with Practice
- When Fear Became the Barrier to Care — Lessons of a Clinical Rapid Response during Operation Metro Surge
- The Future of the USPSTF and Evidence-Based Recommendations
- The Long Shadow of Bedlam
- Adie Tonic Pupil
- Catheter-Directed Thrombolysis in Intermediate-High–Risk Pulmonary Embolism
- Immediate Ambulatory Electrocardiographic Monitoring in Syncope
- Tricuspid-Valve Intervention in Heart Failure
- Timing of PCI in Patients Undergoing Transcatheter Aortic-Valve Implantation
- Pulmonary Denervation for Heart Failure–Related Pulmonary Hypertension
- Clopidogrel or Dual Antiplatelet Therapy in High-Ischemic-Risk Patients
- Prasugrel versus Ticagrelor in Acute Coronary Syndromes
- The Emerging Role of Treatment Policy Implementation Trials in Acute Coronary Syndrome
- Aspirin Omission at the Time of Primary Percutaneous Coronary Intervention in STEMI
- Milvexian with Antiplatelet Therapy after Acute Coronary Syndrome Event
- Prevalence of Silent Atherosclerosis across Adult Life
- Atorvastatin, Cardiovascular Events, and Disability-free Survival in Older Adults
- Targeted Use of Computed Tomographic Coronary Angiography in Acute Chest Pain
- Complete Revascularization Guided by Functional Coronary Angiography in STEMI
- Aficamten for Symptomatic Nonobstructive Hypertrophic Cardiomyopathy
- Response-Tailored or Standard-Duration Antibiotic Treatment for Infective Endocarditis
- Anticoagulation for Atrial Fibrillation with Intermediate Stroke Risk
- Anticoagulation for Atrial Fibrillation with a Single Risk Factor for Stroke
- Eplontersen for Transthyretin Amyloid Cardiomyopathy
- Durability of CRISPR-Cas9 Gene Editing Targeting ANGPTL3 with CTX310
- Phase 3 Trial of Weekly Oral Islatravir–Lenacapavir for HIV-1 Treatment
- Andes Virus — A Clinical Review
- Rivaroxaban Then Aspirin vs. Aspirin Alone after Total Hip or Knee Arthroplasty
- Retraction: Jayne DRW et al. Avacopan for the Treatment of ANCA-Associated Vasculitis, N Engl J Med 2021;384:599-609.
- Lonvoguran Ziclumeran — In Vivo CRISPR Gene Editing in Hereditary Angioedema
- Sodium Bicarbonate for Critically Ill Adults with Metabolic Acidosis and Shock
- Vasopressors or Fluids in Early Septic Shock
- Exa-cel in Children with Transfusion-Dependent β-Thalassemia or Sickle Cell Disease